BTOG 2022 | Optimizing biomarker testing to steer treatment decisions
Neal Navani, MA, MRCP, MSc, PhD, Care Quality Improvement Department, Royal College of Physicians, London, UK, describes strategies to improve biomarker testing to help clinicians make informed treatment decisions for patients with lung cancer. More data is required to understand why certain biopsies fail, and more specialists are required to efficiently process tissue from bronchoscopy to analysis at molecular hubs. The National Optimal Lung Cancer Pathway has additionally suggested optimal processing times for biopsies, which should be met to improve treatment options for patients. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Navani has received honoraria for speaking, advisory boards or travel support from Amgen, Aidence, Astra Zeneca, Lilly, Takeda, Janssen, Merck, MSD, Pfizer, Oncimmune, PeerVoice, OncLive, Bristol-Meyers-Squibb and Olympus, as well as educational grants from Olympus, Cook Medical, Hitachi and Pentax.
